Business
Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker
Early in 2026, Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, completed the branding process for its lead intranasal allergy product, formerly known as PL-14, now officially named NASARIX™. This included trademark screening in the U.S. and European markets and represents a practical step toward potential commercialization for the pre-clinical-stage Israeli biotech.
About this update from Polyrizon Ltd.
[{"type":"text","content":"HONG KONG, Feb. 17, 2026 /PRNewswire/ -- Early in 2026, Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, completed the branding process for its lead intranasal allergy product, formerly known as PL-14, now officially named NASARIX™. This included trademark screening in the U.S. and European markets and represents a practical step toward potential commercialization for the pre-clinical-stage Israeli biotech.","length":479,"tagName":"p"},{"type":"text","content":"Polyrizon is assessing whether NASARIX™ could emerge as a meaningful advancement in allergy treatment.","length":102,"tagName":"p"},{"type":"text","content":"The Allergic Rhinitis Challenge","length":31,"tagName":"p"},{"type":"text","content":"Allergic rhinitis- often called hay fever- remains a widespread and burdensome condition, affecting an estimated 10–30% of the global population. Symptoms, such as sneezing, nasal congestion, itching, and runny nose, disrupt sleep, work, and daily life, with rising prevalence linked to urbanization, pollution, and climate-driven pollen increases. In the U.S., it impacts over 60 million people each year, contributing to significant healthcare spending and lost productivity.","length":477,"tagName":"p"},{"type":"text","content":"The global market for allergic rhinitis treatments is substantial and steadily expanding. Recent estimates value it at around USD 13.08 billion in 2025, projected to reach USD 18.81 billion by 2035 at a compound annual growth rate (CAGR) of 3.7%. Other analyses align closely, forecasting growth from USD 12.24 billion in 2024 to USD 16.97 billion by 2033, driven by demand for intranasal therapies and non-sedating alternatives.","length":429,"tagName":"p"},{"type":"text","content":"Most options are reactive - they relieve symptoms after allergens trigger inflammation. Preventive strategies exist, but few directly block exposure at the nasal entry point in a convenient, drug-free way.","length":205,"tagName":"p"},{"type":"text","content":"NASARIX™'s Differentiated Approach","length":38,"tagName":"p"},{"type":"text","content":"NASARIX™ is a nasal spray based on Polyrizon's Capture and Contain™ (C&C) hydrogel technology. When applied, it forms a thin, bio-adhesive barrier that physically traps allergens (such as pollen, dust mites, pet...